{"pub": "morningstar", "url": "https://morningstar.com/news/dow-jones/201909069520/adc-therapeutics-files-for-ipo", "downloaded_at": "2019-09-07 02:12:29.067186+00:00", "title": "ADC Therapeutics Files for IPO", "language": "en", "text": "By Josh Beckerman\n\nSwitzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.\n\nADC focuses on hematological malignancies and solid tumors.\n\nThe company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.\n\nAuven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.\n\nWrite to Josh Beckerman at josh.beckerman@wsj.com\n\n(END) Dow Jones Newswires\n\nSeptember 06, 2019 20:11 ET (00:11 GMT)\n\nCopyright (c) 2019 Dow Jones & Company, Inc.", "description": "", "authors": [], "top_image": "https://morningstar.com/assets/img/30241a1.png", "published_at": "2019-09-07"}